A foundational assumption in inflammaging research may need recalibration. The enzyme cGAS has been widely regarded as a pro-inflammatory culprit in aging—its sensing of cytoplasmic DNA triggers the immune cascades that damage aged tissues. Blocking cGAS has therefore seemed like an attractive therapeutic avenue. This study in Nature Aging delivers a striking counterargument: removing cGAS altogether makes things considerably worse, not better.
Using cGAS-knockout mice, researchers found that complete loss of the enzyme produced an accelerated-aging phenotype across multiple organs, shortened median lifespan, and elevated frailty scores compared to wild-type controls. The mechanism centered on LINE1 retrotransposons—repetitive genomic elements normally silenced by heterochromatin. Without cGAS, LINE1 elements showed reduced DNA methylation and increased transcription, generating cytoplasmic complementary DNA that paradoxically ignited the very inflammatory signaling cGAS was thought to drive. Crucially, chromatin profiling revealed a flattened H3K9me3 landscape and globally increased chromatin accessibility in knockout cells, implicating cGAS in nuclear heterochromatin maintenance entirely independent of its canonical cytoplasmic DNA-sensing or catalytic roles.
This finding reframes cGAS as a bifunctional protein with distinct nuclear and cytoplasmic roles—a distinction with substantial therapeutic implications. The broader retrotransposon-aging literature has established LINE1 activation as a hallmark of cellular senescence, but this study adds cGAS as an active chromatin guardian rather than a passive responder. The therapeutic takeaway is nuanced: blanket cGAS inhibition, currently explored for autoimmune and fibrotic conditions, could inadvertently accelerate genomic instability and aging biology. Investigators targeting inflammaging may need isoform-specific or compartment-targeted strategies that suppress cytoplasmic cGAS signaling while preserving its nuclear chromatin-organizing function. The mouse-to-human translational gap remains, and lifespan studies in inbred mouse models do not always predict human aging trajectories, but the mechanistic clarity here is compelling enough to reorient therapeutic design.
